Arthramid® Vet is a novel treatment for joint disease. It is a polyacrylamide hydrogel consisting of 97.5% sterile water and 2.5% polyacrimide. The result is a gel that is permeable, biocompatible and has visco-elastic properties, thus making it suitable for injection into equine joints.


Arthramid® Vet is recommended as a therapy for osteoarthritis. Osteoarthritis means inflammation of the joint and usually occurs secondary to wear and tear or following a traumatic injury of the joint. The result is increased fluid in the joint (effusion), cartilage loss, reduced joint mobility and pain (ie lameness). Unfortunately this process is progressive and our therapies are aimed at slowing this progression along with reducing the pain and improving the joint health.

How does ARTHRAMID® VET work?

Studies have shown that Arthramid® Vet integrates with the joint capsule and surrounding joint tissue via vessel in-growth and it functions by creating a continuous dynamic exchange of water. It is hypothesized to create a cushion-like effect in the joint, thus allowing preservation of the joint cartilage and aiding regeneration of any damaged joint cartilage and soft tissues. It is an addition to our arsenal against joint disease and may be beneficial in cases that are no longer responsive to steroid medications alone.


Arthramid® Vet hydrogel is injected into your horse’s affected joints in a process identical to routine joint injections. The area around the joint is clipped and aseptically prepared for sterile injection. Depending on the joint injected, a light dressing may be placed over the injection site for 24 hours.

What happens after the ARTHRAMID® VET injection?

As with all joint injections, we advise box rest initially, followed by a week of light exercise. Results are generally seen 2-3 weeks after the injection and noticeable benefits can last up to 8-12 months according to clinical trials.

ARTHRAMID® VET - Safety Profile

The polyacrylamide hydrogel technology is currently used for facial and body contouring in humans (ie lip filler) and for the treatment of female urinary incontinence. There have been in vitro and in vivo studies performed as well as clinical trials, and the data show that the polyacrylamide gel is well tolerated by patients with no systemic effects and minimal local adverse reactions.